Breckenridge Pharmaceutical Inc, a subsidiary of Japan-based Towa Pharmaceutical, announced on Thursday that it has introduced Zolpidem Tartrate Extended-Release Tablets, USP (generic for Ambien(R) CR) manufactured by Centaur Pharmaceuticals Pvt. Ltd.
Breckenridge Pharmaceutical is to market the product with its own label and offer it in 6.25mg and 12.5mg strengths in bottles of 100.
According to industry sales data, Ambien CR and its generics had annual sales of USD42m during the twelve months ending May 2021. The United States Food and Drug Administration (FDA) earlier granted final approval for this product's Abbreviated New Drug Application.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling